SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-016281
Filing Date
2024-04-16
Accepted
2024-04-16 07:01:54
Documents
16
Period of Report
2024-04-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20240416.htm   iXBRL 8-K 38770
2 EX-10.1 ex101foghornemploymentagre.htm EX-10.1 51371
3 EX-99.1 ex991cfoappointment.htm EX-99.1 15365
7 GRAPHIC image_0.jpg GRAPHIC 64218
  Complete submission text file 0001628280-24-016281.txt   341801

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20240416.xsd EX-101.SCH 1907
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20240416_lab.xml EX-101.LAB 22543
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20240416_pre.xml EX-101.PRE 13047
19 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20240416_htm.xml XML 2829
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 24846091
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)